Walleye Capital
PRDS

Walleye Capital’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Walleye Capital’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-266,782
Closed -$451K – 4533
2022
Q4 		$451K Buy
+266,782
New +$338K 0.01% 1519
2021
Q4 		– Sell
-17,772
Closed -$177K – 2407
2021
Q3 		$177K Sell
17,772
-661
-4% -$6.57K 0.01% 1220
2021
Q2 		$184K Hold
18,433
– – 0.01% 1075
2021
Q1 		$184K Buy
+18,433
New +$191K 0.01% 940

Other funds holding PRDS

Foresite Capital Management V
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VS
VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Platinum Investment Management
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Arena Capital Advisors
Arena Capital Advisors Los Angeles, California $200M AUM 6.35% 1-Year Est. Return

Walleye Capital's PRDS Position: Q1 2023 in Review

Walleye Capital sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q1 2023, closing a stake of 266,782 shares — an estimated $451K sold.

Walleye Capital first reported a position in PRDS in Q1 2021 and held it in 4 quarters. The position peaked at $451K in Q4 2022. 61 funds tracked by Wall St. Rank hold PRDS as of Q1 2023.

  • Walleye Capital reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Walleye Capital sold 266,782 Pardes Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $451K.
  • Walleye Capital first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Walleye Capital's Pardes Biosciences, Inc. Common Stock position peaked at $451K in Q4 2022.
  • 61 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q1 2023.

Based on Walleye Capital's 13F filing for Q1 2023, filed 15 May 2023.